GLP-1 Research Supply After the 2022–2024 Incretin Surge
PeptideLab Editorial
Redaktionsteam
RUO only. We summarize published market context for educators and institutional buyers. Not guidance for personal weight management or off-label drug use.
Clinical demand for GLP-1 receptor agonists outpaced GMP drug capacity in many regions from late 2022 through 2024. That gap did not create a license for consumer “DIY pharmacy” — but it did increase legitimate preclinical interest in reference-grade incretin tools.
What changed in research procurement
- Assay comparability became harder when informal suppliers shipped inconsistent potency.
- Patent-disclosed sequences (e.g. retatrutide, tirzepatide) flooded SPPS suppliers globally — without interchangeable pharmaceutical quality.
- Institutional compliance tightened around RUO labeling and human-use disclaimers.
What qualified labs actually need
- Documented identity per lot (HPLC + MS).
- Stable lyophilized presentation with validated cold chain where required.
- Clear scope — in-vitro and approved animal models, not patient substitutes.
How this differs from retail marketplaces
Domestic consumer platforms actively block INN search terms for prescription intermediates. Export-oriented B2B channels (chemical directories, qualified factories) are where documented research material is discussed — always with COA review, never with injection tutorials.
PeptideLab’s role
We supply RUO lyophilized retatrutide, tirzepatide, and semaglutide with analytics suitable for metabolic pathway work — see products and our resource center for procurement guides.